Vor Biopharma

Vor Biopharma EBITDA per Employee

The EBITDA per Employee of Vor Biopharma (VOR) as of Oct 25, 2026 is -4.89 M USD. In the previous year, EBITDA per Employee was -1.59 M USD — a change of 206.67% (lower).

EBITDA per Employee

-4.89 MUSD

YoY

206.67%

Last updated:

EBITDA per Employee of Vor Biopharma is 2025 -4.89 M USD. EBITDA per Employee of Vor Biopharma was 2024 -1.59 M USD. It decreases by 206.67% lower compared to the previous year.

The Vor Biopharma EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-37,631.58 USD
Jan 1, 2019
-136,644.74 USD
Jan 1, 2020
-570,605.26 USD
Jan 1, 2021
-908,131.58 USD
Jan 1, 2022
-1.23 M USD
Jan 1, 2023
-1.66 M USD
Jan 1, 2024
-1.59 M USD
Jan 1, 2025
-4.89 M USD
The Vor Biopharma EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-4.89 MUSD+206.67%
-1.59 MUSD-3.85%
-1.66 MUSD+34.92%
-1.23 MUSD+35.35%
-908,131.58USD+59.15%
-570,605.26USD+317.58%
-136,644.74USD+263.11%
-37,631.58USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vor Biopharma Stock analysis

What does Vor Biopharma do? Vor Biopharma develops cell therapies for cancer treatment, focusing on hematological malignancies. The company's proprietary platform combines patient engineering with targeted therapies, using expertise in hematopoietic stem cell biology and genome engineering. Its lead product candidate, tremtelectogene empogeditemcel (trem-cel), is designed to replace standard transplant care for acute myeloid leukemia (AML) and other blood cancers. The company conducts clinical trials such as VBP101, a Phase I/II study of VOR33 for AML patients. Vor Biopharma's revenue model relies on developing and advancing its cell therapy pipeline, with trem-cel as the primary focus. The company targets patients with AML and other blood cancers in transplant settings, aiming to replace current standard treatments. Clinical trials like VBP101 are critical for advancing its product candidates toward regulatory approval and commercialization. The firm's financial strategy centers on progressing its lead product through clinical trials to secure market approval. Trem-cel is positioned to address unmet needs in AML treatment, with VBP101 serving as a key study to demonstrate efficacy and safety. As a biopharmaceutical company, Vor Biopharma generates revenue through future product sales after regulatory approval, with no current commercial products. Vor Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vor Biopharma stock

EBITDA per Employee of Vor Biopharma is -4.89 M USD in 2025.

EBITDA per Employee of Vor Biopharma changed from -1.59 M USD to -4.89 M USD, representing a 206.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Vor Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Vor Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Vor Biopharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Vor Biopharma